WA HB1425

Requires health carriers and Medicaid managed care organizations to cover pharmacogenetic testing for psychotropic medications starting January 1, 2026

Prohibits prior authorization or step therapy requirements for this testing, meaning patients do not need to fail on a medication first before accessing the test

Pharmacogenetic testing analyzes a patient's genes to determine how they metabolize or respond to certain medications, including both single-gene and multigene tests

Coverage applies when testing is supported by FDA-approved tests, CMS coverage determinations, nationally recognized clinical practice guidelines, clinical trials, or consensus statements

Applies to commercial health plans under chapter 48.43 RCW, state employee health plans under chapter 41.05 RCW, and Medicaid programs under chapter 74.09 RCW